Intellectual property, pharmaceutical MNEs and the developing world

Journal of World Business

Volumn 44, Issue 2, 2009, Pages 206-215

  Ghauri, Pervez N ^a   Rao, P M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Center for Sustainable Enterprise and Regional Competitiveness   (United States)

Author keywords

Innovation; Intellectual property; Pharmaceuticals; The developing world

Indexed keywords

EID: 60849115546     PISSN: 10909516     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jwb.2008.05.008     Document Type: Article

References (63)

1. Arora A., Fosfuri A., and Gambardella A. Markets for technology (2001), MIT Press, Cambridge, MA
2. Arrow K.J. Economic welfare and allocation of resources for invention. In: Nelson R. (Ed). The rate and direction of incentive activity (1962), Princeton University Press, Princeton, NJ
3. Arrow K.J. New antimalarial drugs: Biology and economics meet. Health and development (2004), International Monetary Fund (December), Washington, DC pp. 20-21
4. Barks-Ruggles E. The Globalization of disease: When Congo sneezes, will California get a cold?. Brookings review (2001), Brookings Institution Press, Washington, DC pp. 30-33
5. Baumol W.J. The free-market innovation machine (2002), Princeton University Press, Princeton, NJ
6. Berndt E.R. Pharmaceuticals in the U.S. health care: Determinants of quantity and price. Journal of Economic Perspectives 16 4 (2002) 45-66
7. Bloom D.E., Canning D., and Jamison D.T. Health, wealth and welfare. Health and development (2004), International Monetary Fund (December), Washington, DC pp. 10-15
8. Buckley P.J., and Casson M. The future of the multinational enterprise in retrospect and in prospect. Journal of International Business Studies 34 (2003) 219-222
9. Bull P.F., and McEvoy G.M. Creating and sustaining ethical capability in the multi-national corporation. Journal of World Business 34 4 (1999) 326-343
10. Burstall M., and Dunning J. International investment in innovation. In: Wells N. (Ed). Pharmaceuticals among sunrise industries (1985), St. Martin's Press, New York 185-197
11. Chesbrough H.W. The era of open innovation. MIT Sloan Management Review 44 Spring (3) (2003) 35-41
12. Christensen J.F. Withering core competency for the large corporation in an open innovation world?. In: Chesbrough H., et al. (Ed). Open innovation: Researching a new paradigm (2006), Oxford University Press, Oxford 35-61
13. Cockburn I., and Henderson R. Public-private interaction in pharmaceutical research. Proceedings of the National Academy of Sciences of the United States 93 (1996) 12725-12730
14. Cohen F. Macro trends in pharmaceuticals. Nature Reviews Drug Discovery 4 January (2005) 78-84
15. Cutler D., Deaton A., and Lleras-Muney A. The Journal of Economic Perspectives 3 Summer (20) (2006) 97-120
16. Danzon P.M. Economics of the pharmaceutical industry. NBER reporter (Fall) (2006), National Bureau of Economic Research, Cambridge, MA
17. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: New estimates of drug development costs. Journal of Health Economics 22 (2003) 151-185
18. Dunning J.H., and Narula R. Multinationals and industrial competitiveness: A new agenda (2004), Edward Elgar, Northampton, MA
19. Fabrizio K.R. The use of university innovation in firm research. In: Chesbrough H., Vanhaverbeke W., and West J. (Eds). Open innovation: Researching a new paradigm (2006), Oxford University Press, Oxford 134-160
20. Forero-Pineda C. The impact of stronger intellectual property rights on science and technology in developing countries. Research Policy 35 6 (2006) 808-824
21. Gallini N.T. The Economics of patents: Lessons from recent U.S. patent reform. The Journal of Economic Perspectives 16 2 (2002) 131-154
22. Ghauri P.N., and Buckley P.J. Globalization, multinational enterprises and world poverty. In: Jain S., and Vachani S. (Eds). Globalization and world poverty (2006), Edward Elgar, Cheltenham 215-227
23. Ghauri P.N., and Cao X. Managing interdependence between multinationals and developing countries. In: Vachani S. (Ed). Corporate governance and development (2006), Edward Elgar, Cheltenham 168-186
24. Ghauri P., Hadjikhani A., and Johanson J. Managing opportunity development in business networks (2005), Palgrave, Basingstock
25. Grabowski H.G., Vernon J., and DiMasi J.A. Returns to research and development for the 1990s new drug introductions. Pharmacoeconomics 20 (2002) 11-29
26. Hall, B. H. (2001). The Global Nature of Intellectual Property: Discussion. Toronto IP Conference: http://emlab.berkeley.edu/users/bhhall/bhpapers.html.
27. Jamison, D. T., Sachs, J. D., & Wang, J. (2001). The effect of the AIDS epidemic on economic welfare in sub-Saharan Africa, Commission on Macroeconomics and Health, CMH Working Paper Series. Paper No. WG1:13.
28. Kremer M. Pharmaceuticals and the developing world. Journal of Economic Perspectives 16 4 (2002) 67-90
29. Kremer M., and Glennerster R. Strong medicine: Creating incentives for pharmaceutical research on neglected diseases (2004), Princeton University Press, Princeton, NJ
30. Lall S. Indicators of the relative importance of IPRs in developing countries. Research Policy 32 (2003) 1657-1680
31. Lanjouw, J. O. (1997). The introduction of pharmaceutical product patents in India: Heartless exploration of the poor and suffering? NBER Working Paper No. 6366. Cambridge, MA: NBER.
32. Lanjouw J.O. Intellectual property and the availability of pharmaceuticals in poor countries. In: Jaffe A.B., Lerner J., and Stern S. (Eds). Innovation policy and the economy (2003), MIT Press, National Bureau of Economic Research Cambridge, MA 91-130
33. Lanjouw, J. O. (2005). Patents, price controls and access to new drugs: How policy affects global market entry. National Bureau of Economic Research Working Paper 11321. Cambridge, MA: NBER.
34. Leebron D.W. Lying down with procrustes: An analysis of harmonization claims. In: Bhagwati J., and Hudec R.E. (Eds). Fair trade and harmonization (1996), The MIT Press, Cambridge, MA 41-118
35. Lichtenberg F.R. Pharmaceutical innovation, mortality reduction and economic growth. In: Murphy K.M., and Topel R.H. (Eds). Measuring the gains from medical research (2003), The University of Chicago Press, Chicago 74-109
36. Lodge G., and Wilson C. A corporate solution to global poverty: How multinationals can help the poor and invigorate their own legitimacy (2006), Princeton University Press, Princeton, NJ
37. Mansfield, E. (1994). Intellectual Property Protection, Foreign Direct Investment and Technology Transfer. International Finance Corporation, Discussion Paper Number 19. Washington, DC: World Bank, pp. 1-43.
38. McNeil Jr., D. G. (2007). Low-cost antimalarial pill available. (March 1) New York Times.
39. Mehta S. The emerging role of academia in commercializing innovation. Nature Biotechnology 22 (2004) 21-24
40. Moses III H., Dorsey R.E., Matheson D.H.M., and Their S.O. Financial anatomy of biomedical research. Journal of American Medical Association 294 11 (2006) 1333-1342
41. Mowery D.C., Nelson R.R., Sampat B.N., and Ziedonis A.A. The growth of patenting and licensing by U.S. universities: An assessment of the effects of the Bayh-Dole act of 1980. Research Policy 30 (2001) 99-119
42. Nadiri, M. I. (1993). Innovations and technological spillovers. NBER Working Paper # 4423. Cambridge, MA: National Bureau of Economic Research.
43. Narula R. Knowledge creation and why it matters for development: The role of TNCs in globalization of R&D and developing countries. Proceeding of Expert Meeting (2005), United Nations, New York
44. National Science Board (NSB). Science and engineering indicators (2006), US Department of Commerce, Washington, DC
45. Nordhaus W.D. The health of nations. In: Murphy K.M., and Topel R.H. (Eds). Measuring the gains from medical research (2003), The University of Chicago Press, Chicago 9-40
46. Organization for Economic Co-operation and Development (OECD) (2006). Innovation in pharmaceutical biotechnology: Comparing national innovation systems at the sectoral level, Paris.
47. Pharmaceutical Research Manufacturers of America (PhRMA). Pharmaceutical industry profile 2005 (2005), PhRMA, Washington, DC
48. Pharmaceutical Research Manufacturers of America (PhRMA). Pharmaceutical industry profile 2006 (2006), PhRMA, Washington, DC
49. Pisano G. Profiting from intellectual property revolution. Research Policy 35 (2006) 1122-1130
50. Pisano G.P. Science business (2006), Harvard Business School Press, Boston, MA
51. Rao P.M., and Klein J.A. Growing importance of marketing strategies for the software industry. Industrial Marketing Management 23 1 (1994) 29-37
52. Rao P.M. Intellectual property protection and foreign direct investment: A global pharmaceutical industry perspective. In: Rao C.P. (Ed). Globalization, privatization and free market economy (1998), Quorum Books, Westport, CT 232-253
53. Redding, S., Griffith, R., Van Reenen, J. (2000). Mapping the two faces of R & D: Productivity growth in a panel of OECD industries. CEPR Discussion Paper # 2457.
54. Rugman A.M., and D'Cruz J. Multinationals as flagship firms: Regional business networks (2000), Oxford University Press, Oxford
55. Scherer F.M. The pharmaceutical industry-Prices and progress. The New England Journal of Medicine 351 August (2004) 927-932
56. Stiglitz J.E. Globalization and its discontents (2003), W.W. Norton & Co., New York
57. The Economist. Millenium development goal: The eight commandments. The Economist July (2007) 26-29
58. Vachani S., and Smith N.C. Socially responsible pricing: Lessons from pricing of AIDS drugs in developing countries. California Management Review 47 (2004) 117-144
59. West J., Vanhaverbeke W., and Chesbrough H. Open innovation: A research agenda. In: Chesbrough H., et al. (Ed). Open innovation: Researching a new paradigm (2006), Oxford University Press, Oxford 285-307
60. World Bank. Poverty trends and voices of the poor (2001), The World Bank, Washington, DC
61. World Health Organization (WHO). World health report (2001), WHO, Geneva
62. World Health Organization (WHO). (2005). www.who.int/entitiy/3by5/annex/regions.pdf.
63. World Trade Organization (WTO). (2001). Ministerial Declaration. WT/MIN(01)DEC/1. (November).